Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.
Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.


RARE DISEASE
Acute graft versus host disease
Acute graft versus host disease
Acute graft versus host disease
Drug discovery
28
drugs
With orphan designations
Rare immune diseases
Acute graft versus host disease
Overview
Acute graft-versus-host disease (aGVHD) is a life-threatening immune-mediated complication occurring post-allogeneic hematopoietic stem cell transplantation (HSCT), where donor T cells attack host tissues. It primarily affects the skin (rash), liver (jaundice), and gastrointestinal tract (diarrhea), typically emerging within 100 days post-transplant [1][2][5]. Incidence ranges from 35%–50%, with severity and prognosis influenced by HLA compatibility, conditioning intensity, and prophylaxis regimens [1][3][15]. First-line therapy involves corticosteroids, while refractory cases require salvage immunosuppression [2][8][16].
Burden
Healthcare utilization: Grade III/IV aGVHD doubles hospitalization duration (median 28 vs. 22 days) and ICU admission rates (13% vs. 6%) [4][7]
Economic impact: Mean 100-day costs reach $120,929 for severe cases, driven by prolonged hospital stays and readmissions [4]
Mortality: >50% non-relapse mortality in steroid-refractory cases, particularly with lower GI involvement [4][8][15]
Therapies
First-line: High-dose corticosteroids (e.g., methylprednisolone 2 mg/kg/day) [2][10][16]
Second-line: Anti-TNF agents (infliximab), JAK inhibitors (ruxolitinib), or interleukin-2 receptor antagonists [8][16][18]
Prophylaxis: Calcineurin inhibitors (tacrolimus) combined with methotrexate or mycophenolate mofetil [3][5][8]
Categories: rare immunological diseases, rare transplant-related disorders
Research Papers
3,442 drug discovery papers about Acute graft versus host disease, with 2 first-in-class and 22 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
3,442 drug discovery papers about Acute graft versus host disease, with 2 first-in-class and 22 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
categories:
Small molecules
small molecules
2026-09-30 | Evaluation and Extrapolation of a Tacrolimus Population Pharmacokinetic Model in Adult Recipients of Allogeneic Hematopoietic Cell Transplantation Receiving Post-Transplant Cyclophosphamide.
Allogeneic hematopoietic cell transplant (allo-HCT) is potentially curative for many hematologic diseases but complicated by acute graft-versus-host disease (aGVHD). While tacrolimus remains the cornerstone of aGVHD prophylaxis, regimens are increasingly including post-transplant cyclophosphamide (PTCy). This single-center study evaluated a previously published tacrolimus population pharmacokinetic (popPK) model developed from allo-HCT recipients administered standard (tacrolimus plus methotrexate) aGVHD prophylaxis for generalizability to PTCy recipients. Adult allo-HCT recipients treated with PTCy for aGVHD prophylaxis were included. Applicability of the established popPK model to the PTCy population was based on an evaluation of simulated to observed concentration ratios, and the distribution was interpreted with respect to a clinical equivalence range (0.8 to 1.25). The model was refit using data from both the standard and PTCy cohorts to describe the PK and support extrapolation to the PTCy population. Individual PK parameters from PTCy recipients were used to simulate steady-state concentrations (Ctrough, ss) using the current institutional weight-based dosing strategy and the proposed model-informed precision dosing (MIPD) algorithm. The proportion of patients predicted to experience a subtherapeutic Ctrough, ss (<5 ng/mL) was compared between dosing strategies. Five hundred and ninety-three tacrolimus Ctrough, ss values from 95 allo-HCT recipients who received PTCy were included. The previous model did not successfully predict tacrolimus Ctrough, ss values among PTCy patients, but highlighted similarities between clearance in PTCy and standard aGVHD prophylaxis patients who received reduced-intensity conditioning. Dosing simulations suggested a decreased proportion of PTCy patients would experience subtherapeutic tacrolimus Ctrough, ss with MIPD (3%) compared to conventional weight-based dosing (23%).
2026-09-27 | Successful Management of Severe Hepatic Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in a Child With β-Thalassemia Major: Clinical Lessons From Early Therapeutic Escalation.
Severe hepatic acute graft-versus-host disease can occur early after allogeneic hematopoietic stem cell transplantation without skin involvement, presenting with rapidly progressive cholestatic liver dysfunction. Early recognition and prompt escalation to multimodal immunosuppressive therapy achieve complete biochemical remission and durable hematopoietic recovery, highlighting the crucial role of early, multidisciplinary pediatric management.
2026-09-15 | Chidamide plus venetoclax as effective and safe maintenance therapy in high-risk acute myeloid leukemia and myelodysplastic syndrome post-transplantation.
Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the leading cause of treatment failure in high-risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), yet effective maintenance strategies are currently lacking. The combination of chidamide (CHI) and venetoclax (VEN) represents a novel approach. However, real-world data on its use are limited. In this study, eighteen high-risk transplant recipients received maintenance therapy with CHI (5 mg/day on days 1-7 or 1-14) plus VEN (100 mg on day 1, then 200 mg on days 2-7 or 2-14) every 2 months. Endpoints included overall survival (OS), disease-free survival (DFS), cumulative incidence of relapse (CIR), non-relapse mortality (NRM), and safety. After a median follow-up of 708 days, the 2-year OS and DFS were 73.9% and 56.6%, respectively. The 2-year CIR was 28.9%, and the 2-year NRM rate was 22.5%. The most common adverse events were hematologic, including neutropenia (13 episodes), thrombocytopenia (7), and anemia (7), all of which were manageable. No treatment-related mortality, tumor lysis syndrome, or severe acute graft-versus-host disease (GVHD) occurred. In conclusion, CHI plus VEN as post-transplant maintenance therapy shows encouraging efficacy and a manageable safety profile in high-risk AML/MDS patients, representing a promising strategy for relapse prevention.
2026-09-15 | Cytokine release syndrome in adults with acute leukemia after allo-HCT with posttransplant cyclophosphamide prophylaxis.
Cytokine release syndrome (CRS) is a common complication following allogeneic hematopoietic cell transplantation (allo-HCT) with posttransplant cyclophosphamide (PTCy). However, its incidence, risk factors, and clinical significance remain incompletely characterized. We retrospectively analyzed 362 adult patients with acute leukemia in complete remission who underwent PTCy-based allo-HCT at a single center between 2020 and 2025. CRS was observed in 69 patients (19.1%); all cases were grade 1-2 by the 2019 ASTCT criteria. Incidence differed significantly by donor type: 39.5% in haploidentical, 15.4% in mismatched unrelated (MMUD), 8.0% in matched unrelated, and 1.4% in matched related donor recipients (p < 0.001). On multivariable analysis, CRS risk increased with HLA disparity versus matched donors (MMUD OR 2.92, p = 0.026; haploidentical OR 12.2, p < 0.001), and was higher with peripheral blood than bone marrow grafts (OR 3.59, p = 0.025). CRS was associated with higher incidence of grade II-IV acute graft-versus-host disease (aGVHD) (35 vs 18%, p = 0.002), while survival, non-relapse mortality, and relapse incidence did not differ significantly. Histological examination of CRS-associated cutaneous lesions demonstrated perivascular lymphocytic dermatitis without features of aGVHD. Ruxolitinib administration for extensive cutaneous involvement was associated with resolution of skin manifestations. HLA mismatch and peripheral blood grafts are associated with CRS, which may precede subsequent aGVHD.
2026-09-09 | Thiolutin alleviates acute graft-versus-host disease (aGVHD) in a mouse model of allogeneic hematopoietic stem cell transplantation.
Acute graft-versus-host disease (aGVHD) is a major, life-threatening complication in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), and the development of novel molecular-targeted therapies for aGVHD is urgently needed. Thiolutin (THL), a disulfide-containing antibiotic, inhibits the activity of the BRCC3-containing isopeptidase complex and thereby suppresses NLR pyrin domain-containing protein 3 (NLRP3) inflammasome activation. Here, we investigated the effect of THL on aGVHD in a mouse model of allo-HSCT. We found that THL significantly improved survival in aGVHD recipients, reduced weight loss and clinical scores, and attenuated pathological changes in aGVHD target organs, including the liver, small intestine, and colon. Furthermore, THL diminished donor T-cell activation and infiltration into target organs and promoted the expansion of regulatory T cells. THL also inhibited NLRP3 inflammasome activation and reduced the production of proinflammatory cytokines, including tumor necrosis factor (TNF), interferon γ (IFN-γ), interleukin (IL)-2, IL-17A, and IL-1β. This study reveals a previously unrecognized role of THL in regulating aGVHD and highlights its potential as an anti-inflammatory therapeutic agent for clinical development in patients undergoing allo-HSCT.
cell therapies
2026-09-04 | Graft CD3+/CD4 - CD8- T-cell ratio: a predictor of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation in pediatric patients.
Acute graft-versus-host disease (aGVHD) remains a major complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study investigated the association between the graft CD3+/CD4 - CD8- T-cell ratio and the incidence of aGVHD in pediatric recipients. A total of 112 pediatric patients with high-risk hematologic malignancies undergoing allo-HSCT were enrolled in this retrospective study. Associations between the graft CD3+/CD4 - CD8- T-cell ratio and aGVHD were evaluated using Fine-Gray regression models. Receiver operating characteristic (ROC) analysis was performed to determine the predictive performance and optimal cutoff value of the graft CD3+/CD4 - CD8- T-cell ratio. Spearman's rank correlation coefficient was used to assess correlations among different cellular subsets. The day-100 cumulative incidence of grade II-IV aGVHD was 41.1%. In multivariable analysis, the graft CD3+/CD4 - CD8- T-cell ratio was independently associated with grade II-IV aGVHD. ROC analysis identified 56 as the optimal cutoff value for the graft CD3+/CD4 - CD8- T-cell ratio. Patients with a high ratio had a significantly higher incidence of grade II-IV aGVHD than those with a low ratio (56.3% vs. 20.8%, P < 0.001), whereas no significant differences were observed in disease relapse or cytomegalovirus (CMV) infection. The graft CD4 - CD8- T-cell dose was positively correlated with early peripheral CD4 - CD8- T-cell recovery after transplantation. A higher graft CD3+/CD4 - CD8- T-cell ratio is independently associated with an increased risk of day-100 grade II-IV aGVHD in pediatric allo-HSCT recipients. Optimizing the graft CD3+/CD4 - CD8- T-cell ratio may help mitigate aGVHD, thereby serving as a practical biomarker for individualized aGVHD risk stratification.
2026-08-27 | Keratin 8 enhances the efficacy of mesenchymal stem cells in preventing acute graft-versus-host disease.
Acute graft-versus-host disease (aGVHD) remains a leading cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The development of methods that preserve graft-versus-leukemia (GVL) activity while preventing aGVHD remains a long-sought goal. Recent studies suggest that mesenchymal stem cells (MSCs), particularly human umbilical cord-derived MSCs (HUC-MSCs), are effective at mitigating aGVHD, yet their varied efficacy remains poorly understood. We performed a comprehensive analysis of MSCs heterogeneity through single-cell transcriptomic mapping across nine human tissue sources and identified the keratin 8 high-expression (KRT8+) subpopulation of HUC-MSCs with enhanced functional properties. We further validated the functional roles of the KRT8+ subpopulation through lentivirus-mediated KRT8 overexpression. Bulk RNA sequencing was used to analyze the genomic impact of KRT8 overexpression. Additionally, we examined the effects of KRT8 overexpression on cellular senescence via Western blotting and β-galactosidase (SA-β-gal) staining. The immunosuppressive function of HUC-MSCs was evaluated by coculturing them with CD3+ T Cells and liver organoids. Cell migration ability was assessed through Transwell assays and PKH26 dye labeling in vivo. An MHC-mismatched GVHD mice model (C57BL/6J to BALB/c) was established to test the therapeutic effect of HUC-MSCs. Clinical signs of aGVHD were monitored, and pathological changes were analyzed using hematoxylin and eosin staining. The GVL effect was evaluated through the inoculation of luciferase-transfected A20 cells and bioluminescence imaging. KRT8 was expressed predominantly in HUC-MSCs. Compared with the KRT8 low-expression (KRT8lo) subpopulation of HUC-MSCs, the KRT8+ subpopulation presented increased stemness and reduced immunogenicity. KRT8 overexpression in HUC-MSCs significantly ameliorated aGVHD in vivo. Importantly, increased KRT8 expression in HUC-MSC did not impaire GVL activity in A20 lymphoma cells. Functional experiments further confirmed that HUC-MSCs with increased KRT8 expression significantly reduced cellular senescence by increasing enhancer of zeste homolog 2 (EZH2)-mediated histone h3 lysine 27 trimethylation (H3K27me3). This upregulation resulted in increased secretion of hepatocyte growth factor (HGF). This, in turn, suppressed T-cell proliferation and activation, significantly reducing liver organoid damage in vitro. Our results suggest that the infusion of KRT8+ HUC-MSCs enhances the efficacy of preventing aGVHD but does not interfere with the GVL effect. This strategy represents a promising therapeutic advancement in the setting of allo-HSCT.
2026-08-19 | Fecal microbiota transplantation in the treatment of acute graft-versus-host disease: A retrospective study performed by the Complications Working Party and Pediatric Diseases Working Party of the EBMT.
Acute graft-versus-host disease (aGvHD) is a major cause of non-relapse mortality following allogeneic hematopoietic stem cell transplantation (alloHSCT). While corticosteroids are the standard first-line therapy, approximately half of the patients become steroid-refractory or -dependent (SR/D). Fecal microbiota transplantation (FMT) has emerged as a therapeutic strategy targeting the underlying gut dysbiosis associated with aGvHD. This study presents retrospective data on FMT for SR/D-aGvHD. This retrospective, multicenter study was conducted by the Complications Working Party of the EBMT. Data were collected from 9 centers on patients who received FMT for the treatment of SR/D-aGvHD between 2014 and 2019. The primary endpoint was the overall response rate (ORR) at day 28 post-FMT. Forty-seven patients were analyzed. The primary indication for FMT was gastrointestinal aGvHD (GI-aGvHD). In this heavily pre-treated, ruxolitinib-naïve population, the ORR at day 28 was 60.5%, increasing to 69.2% by day 56. At last follow-up, 23 patients (64% of survivors) had no symptoms of aGvHD. Adverse events related to FMT were reported in 24 patients (51.1%). A clinically significant secondary benefit was the 54.5% decolonization rate of antibiotic-resistant bacteria. In this cohort FMT demonstrated efficacy for SR/D-aGvHD, with response rates comparable to those of modern targeted agents.
2026-08-18 | Extracorporeal Photopheresis in Tandem With Continuous Renal Replacement Therapy: A Case Report.
The use of therapeutic plasma exchange in tandem with continuous renal replacement therapy (CRRT) and extracorporeal membrane oxygenation (ECMO) has been well described; however, evidence showing the use of extracorporeal photopheresis (ECP) in tandem is lacking. Here we report a consult to perform ECP in tandem with CRRT for a 26-year-old female with a history of severe aplastic anemia who underwent allogeneic hematopoietic stem cell transplant, complicated by steroid-refractory acute graft-versus-host disease, vaso-occlusive disease, thrombotic microangiopathy, adenoviremia, and acute renal and respiratory failure. We performed six tandem ECP procedures (seven total) over 19 days, until the patient's decline resulted in compassionate discontinuation of care. During our procedures, CRRT managed the ionized calcium and adjusted the calcium infusion rate accordingly. We encountered red blood cell and optic bowl sensor alarms during ECP. This case, to our knowledge, is the first to describe the inpatient use of ECP in tandem with CRRT.
2026-07-22 | GZMK-expressing tissue-resident memory CD8+ T cells participate in human intestinal acute graft-versus-host disease.
Intestinal acute graft-versus-host disease (aGVHD) is a common life-threatening complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although tissue-resident memory T (TRM) cells are thought to play a pathophysiological role in animal models of aGVHD, little is known about the role of distinct subsets of TRM cells in human intestinal aGVHD. Herein, we combined multiplex immunohistochemical staining with single-cell RNA sequencing to elucidate the differentiation trajectory, lineage commitment, clonal expansion, and functional properties of distinct CD8+ TRM cell subsets in human intestinal aGVHD. We identified a predominant GZMK+CD8+ TRM subset, characterized by the GZMK and CD49A markers. Intestinal aGVHD was associated with infiltration of GZMK+CD8+ T cells with TRM features, which showed enhanced clonal expansion, IFN signaling pathway-associated proinflammatory pathway expression, and lineage bifurcation differentiation properties. High GZMK+CD8+ TRM subset infiltration was associated with greater human intestinal aGVHD severity and poor prognosis. Together, our studies highlight the importance of the GZMK+CD8+ TRM subset in human intestinal aGVHD, and interest for designing GZMK+CD8+ TRM cell-targeted therapies.
proteins
2026-09-24 | Prognostic factors of acute and chronic graft-versus-host disease in pediatric patients undergoing bone marrow haploidentical transplant with post-transplantation cyclophosphamide.
Haploidentical hematopoietic stem cell transplantation has become an important therapeutic option for pediatric patients lacking an HLA-identical donor. This study aimed to identify clinical and transplant-related predictors of graft-versus-host disease in Tunisian children undergoing haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. A retrospective study, conducted at the National Blood Transfusion Center, in collaboration with the National Bone Marrow Transplantation Center, included 47 pediatric patients transplanted between January 2019 and December 2023. Associations with acute and chronic graft-versus-host disease were assessed using contingency tables with odds ratios and 95% confidence intervals, followed by multivariate logistic regression for relevant variables. Forty-eight transplant procedures were analyzed. In the univariate analysis, most parameters, including graft cellular content, conditioning regimen, donor age, underlying disease, donor-specific antibodies and ABO incompatibility, were not associated with graft-versus-host disease. In contrast, donor-recipient sex mismatch significantly increased the risk of acute graft-versus-host disease (OR = 10.0; 95% CI: 2.26-44.20; p = 0.0024) and was confirmed as an independent predictor on multivariate analysis (OR = 17.7; 95% CI: 0.13-297.9; p = 0.0068). No variable emerged as a significant determinant of chronic graft-versus-host disease. In this cohort, donor-recipient sex mismatch was the main risk factor for acute graft-versus-host disease, while no clear predictor was identified for chronic disease. Larger prospective studies are needed to validate these findings and to refine predictive models, with the ultimate aim of optimizing haploidentical hematopoietic stem cell transplantation protocols and improving outcomes.
2026-09-23 | Paeoniflorin prevents acute graft-versus-host disease while preserving graft-versus-tumor effects.
Acute graft-versus-host disease (aGVHD) remains a major complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study investigated the preventive effects of paeoniflorin (PF), a natural monoterpene glycoside, on aGVHD. Candidate herb-derived compounds against aGVHD were screened using SymMap, HERB, ADMETlab, and InflamNat, followed by molecular docking. The preventive effects of PF were evaluated in major histocompatibility complex (MHC)-mismatched murine aGVHD models. An entire-process paeoniflorin (EP-PF) regimen, involving donor pretreatment before transplantation and recipient treatment after transplantation, was proposed for enhancing the preventive effect. Survival, body weight, clinical score, hematopoietic reconstitution, donor T cell infiltration, cytokine and chemokine levels, gut injury, apoptosis, gut microbiota, transcriptomic changes, and graft-versus-tumor (GVT) activity were assessed. PF was identified as a promising multi-target compound for aGVHD prevention. PF reduced clinical severity, body weight loss, and mortality, while improving hematopoietic recovery and increasing hematopoietic stem/progenitor cell (HSPC) numbers. EP-PF regimen showed stronger protection than recipient-only PF administration. Mechanistically, EP-PF reduced intestinal donor cluster of differentiation 4 (CD4) positive and cluster of differentiation 8 (CD8) positive T cell infiltration, partially restored CD4+/CD8+ T cell balance, and reversed inflammatory transcriptional programs in donor T cells. Moreover, EP-PF balanced serum levels of cytokines and chemokines, preserved gut barrier integrity, reduced intestinal apoptosis, and partially corrected gut microbiota dysbiosis. Importantly, EP-PF preserved donor cell-mediated tumor control in a green fluorescent protein (GFP)-labeled A20 GVT model. PF also directly inhibited the proliferation of hematologic tumor cells and promoted their apoptosis in vitro and in vivo. PF prevents experimental aGVHD through coordinated regulation of donor T cell responses, inflammatory mediators, hematopoietic reconstitution, intestinal barrier injury, apoptosis, and gut microbiota, while preserving GVT activity. These findings support PF as a potential prophylactic candidate for allo-HSCT.
2026-09-08 | Etanercept in Steroid-Refractory Acute Graft Versus Host Disease: Clinical Response, Toxicity, and Long-Term Outcomes.
Steroid refractory acute graft versus host disease (SR-aGVHD) is seen in 30%-40% of patients undergoing allogeneic hematopoietic stem cell transplant (allo HSCT). We report our experience with etanercept (ETA) as a first-line treatment for SR-aGVHD during a period when ruxolitinib was not available in India. We retrospectively analysed 43 allo HSCT patients from 2010 to 2019 who received ETA for SR-aGVHD. The primary objective was to assess the overall response rate with etanercept. Secondary objectives included overall survival (OS), organ specific responses, causes of mortality and identification of factors associated with survival and see its utility in the current ruxolitinib era. The response rates (overall response rate [ORR] - complete response [CR] + very good partial response [VGPR] + partial response [PR]) at Day 28 was 69%. The organ-specific ORR was 70% (lower gut), 67% (skin), and 50% (liver). The median OS of responders at Day 28 from ETA start was 6.8 months versus 2.8 months in non-responders (p=0.0008). Patients in whom a reduction in the systemic steroid dose of ≥ 30% by Day 28 from ETA start was possible had a significantly longer median OS (9.5 months versus 3.5 months; p=0.0001). In multivariate analysis, steroid dose reduction of ≥ 30% by Day 28 of the start of ETA was a significant factor for survival (p=0.015). The cause of death in the majority was infection (90%). ETA, used as a second-line agent, has shown an acceptable ORR for SR-aGVHD in our cohort. Despite the good response rates, the group had a high transplantation-related mortality. Infections were the major cause of mortality, and early tapering of systemic steroids may be the key to improving outcomes. In the current ruxolitinib era, etanercept may hold a place in patients where ruxolitinib has failed or is not feasible.
2026-08-09 | Pegtarazimod limits acute graft-versus-host disease mortality and severity in mice and is tolerated in patients.
The success of allogeneic hematopoietic cell transplantation (allo-HCT) is limited by acute graft-versus-host disease (aGVHD). We have previously reported that neutrophils can exacerbate tissue damage caused by conditioning regimens. Pegtarazimod is a synthetic peptide, derived from the capsid protein of human astrovirus serotype 1, that was shown to reduce neutrophil effector functions. Therefore, we evaluated the therapeutic activity of pegtarazimod against aGVHD. Pegtarazimod significantly reduced aGVHD-related mortality, histological aGVHD severity, and pro-inflammatory cytokines in multiple in vivo mouse models, while maintaining the anti-leukemia effect. Mechanistically, pegtarazimod reduced inflammation by decreasing ROS production as investigated using allo-HCT recipient mice with genetic inactivation of NADPH oxidase (NOX2) in the bone marrow. In addition to the anti-inflammatory effect, pegtarazimod protected intestinal organoids against TNF-induced toxicity and oxidative DNA damage. In the phase-2 clinical trial AURORA, pegtarazimod treatment was well-tolerated in patients with corticosteroid-refractory (SR) aGVHD (NCT06343792) with an overall response rate (ORR) of 4/7 patients at day 28. In summary, pegtarazimod reduced aGVHD in mice by suppressing pro inflammatory neutrophil effector functions and preserving enterocyte integrity. The clinical trial data support tolerability of pegtarazimod in aGVHD patients and further studies are needed to determine efficacy.
2026-07-31 | Gastrointestinal acute graft versus host disease: a translational perspective from pathogenesis to precision prevention and treatment.
Allo-HSCT represents a curative option for various hematological disorders. However, aGVHD remains the leading cause of non-relapse mortality following transplantation. The gastrointestinal tract is the most severely affected and prognostically unfavorable target organ in aGVHD, driven by donor T-cell-mediated epithelial damage, microbiota dysbiosis-driven immune amplification, and a self-perpetuating cycle of barrier disruption. Recent multi-omics studies have identified key pathogenic mechanisms, including microbiota-driven MHC-II expression and immunomodulation by microbial metabolites. Biomarker-driven risk stratification using the MAGIC algorithm has shifted management toward precision medicine, while targeted agents such as ruxolitinib, vedolizumab, and microbiota-directed interventions are reshaping therapeutic strategies. Novel interventional modalities, including FMT, recombinant LCN2, and specific bile acids, have forged innovative avenues that synergize microbiota-directed approaches with immunomodulation for the prevention and treatment of GI-aGVHD. This review systematically delineates the latest advances in the pathogenesis, risk stratification, and therapeutic strategies for GI-aGVHD, and envisions future directions for precision medicine centered on personalized microbiota-immune interventions.
antibodies
2026-09-29 | Graft-Versus-Tumour Effect Following Allogeneic Haematopoietic Stem Cell Transplantation in a Paediatric Patient With Mogamulizumab-Treated Primary Cutaneous Peripheral T-Cell Lymphoma.
Primary cutaneous peripheral T-cell lymphoma, not otherwise specified (pcPTCL-NOS), is exceptionally rare in children, and evidence guiding diagnosis and treatment is limited. A 10-year-old boy with pcPTCL-NOS refractory to chemotherapy received mogamulizumab prior to allogeneic haematopoietic stem cell transplantation (allo-HSCT). Despite a 60-day washout period, he developed prolonged steroid-refractory acute graft-versus-host disease requiring ruxolitinib and extracorporeal photopheresis. Concurrently, transient skin lesions developed at previous lymphoma sites and regressed spontaneously, with biopsy supporting the interpretation of visible graft-versus-lymphoma. This case underscores the need to optimise allo-HSCT timing after mogamulizumab and preserve graft-versus-lymphoma effect while limiting graft-versus-host disease. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
2026-09-01 | Association of Nutrition Intake Adequacy with Clinical Outcomes in Hospitalized Hematopoietic Cell Transplant Patients: A Retrospective Cohort Study.
Patients undergoing hematopoietic cell transplantation (HCT) face nutrition-impacting symptoms that compromise oral intake and increase malnutrition risk. The independent relationship between nutrition intake adequacy and clinical outcomes in this population remains incompletely characterized. To determine whether adequate intake (≥75% of estimated needs) during HCT admission is independently associated with hospital length of stay (LOS), 30-day readmission, and acute graft-versus-host disease (GVHD). Twelve-month retrospective cohort study using electronic medical records between June 15, 2022 - June 15, 2023. Nutrition intake was averaged across admission from registered dietitian assessments and categorized as adequate (≥75%) or inadequate (<75%). /Setting: 283 adults (85 autologous, 198 allogeneic) aged ≥18 years admitted to Stanford Health Care for HCT with a length of stay ≥7 days. Hospital LOS, 30-day readmission, and acute GVHD within 100 days. Multivariable linear regression for LOS and logistic regression for readmission and GVHD, each adjusted for age, gender, race/ethnicity, and BMI. In autologous HCT patients, adequate intake was independently associated with shorter LOS (β = -1.91 days, 95% CI -3.33 to -0.48; P = 0.009), and malnutrition at discharge with longer LOS (β = 1.43 days, 95% CI 0.02 to 2.91; P = 0.04). Sensitivity analyses for autologous HCT patients with adequate intake, excluding patients who received enteral or parenteral nutrition support, did not alter these findings (β = -1.51 days, 95% CI -2.99 to -0.03; P = 0.048). In allogeneic patients, no significant associations were found between intake and LOS after adjustment. Intake was not associated with 30-day readmission or acute GVHD in either group. Among autologous HCT patients, adequate intake was associated with shorter LOS and discharge malnutrition with longer LOS. Optimizing nutritional status may help improve outcomes and reduce hospitalization in this population.
2026-08-21 | Safety and Efficacy of Vedolizumab for the Patients With Gastrointestinal Acute Graft-Versus-Host Disease Refractory to Steroid Treatment After Allogeneic Hematopoietic Stem Cell Transplantation: A Real-World, Retrospective Multicenter Study (VAST Study).
Steroid-refractory (SR) gastrointestinal (GI) acute graft-versus-host disease (aGVHD) is the major cause of early mortality after allogeneic hematopoietic stem cell transplantation. Vedolizumab could be used as the second- or third-line treatment of GI-aGVHD. Our real-world, retrospective multicenter study, in which 100 SR-GI-aGVHD patients who received vedolizumab were enrolled, confirmed its effectiveness. Note that 411 SR-GI-aGVHD patients who received the best available treatments (BATs) during the same period were enrolled as controls. Inverse probability of treatment weighting (IPTW) and propensity score matching (PSM) were conducted as sensitivity analyses. The overall response rates (ORRs) for SR-GI-aGVHD on day 28 and at any time point were 68.0% and 81.0%, respectively, and the 2-year probabilities of overall survival and nonrelapse mortality were 58.3% and 31.9%, respectively, after vedolizumab treatment. Multivariate analysis revealed that initiating vedolizumab treatment within 7 days after SR-aGVHD onset could help improve the ORR. In the sensitivity analysis, compared with the BATs, vedolizumab improved the ORR and complete response rate, particularly in the stage 3-4 SR-GI-aGVHD subgroup, and it reduced the infection rate after IPTW and PSM adjustment. These findings confirmed the efficacy of vedolizumab in a real-world setting, which can help to control SR-GI-aGVHD more effectively and safely.
2026-07-28 | IL-39/IL-39R Signaling Drives Acute Graft-versus-Host Disease by Promoting Pathogenic T-Cell Responses 2259690
Abstract Introduction Acute graft-versus-host disease (aGVHD) remains a life-threatening complication of allogeneic hematopoietic cell transplantation. Among IL-12 family cytokines, the newly identified IL-39, composed of IL-23p19 and EBI3, ligands IL-39 receptor, a complex of IL-23Rα and gp130. IL-39 has been implicated in inflammatory disorders, but its contribution to aGVHD and graft-versus-leukemia (GVL) remains undefined. Methods Murine and human T cells were stimulated with allogeneic APCs in the presence of recombinant human IL-39 (rhIL-39) to test the effect of IL-39 in T-cell response in vitro. Proximity ligation assay (PLA) was used to detect IL-23Rα/GP130 heterodimerization. T-cell pathogenicity in GVHD was measured in murine allogeneic bone marrow transplantion (BMT). The GVL activity was assessed using MLL-AF9 leukemia challenge. A xenogeneic GVHD (xeno-GVHD) model with human PBMCs was used to evaluate IL-39’s effect on human T-celll responses. Results rhIL-39 enhanced proliferation and production of IFN-γ, TNF-α, and GM-CSF, promoted Th1/Th17 polarization, and suppressed Foxp3+Treg differentiation in murine and human T cells. It induced robust STAT1/3 phosphorylation in IL-23Rαhigh Th17 cells and PLA assay confirmed IL-23Rα/gp130 heterodimerization. In murine BMT models, recipients receiving IL-23Rα-/- or DKO donor cells exhibited less GVHD compared to those of WT or IL-12Rβ1-/- cells while preserving GVL activity. rhIL-39 markedly increased GVHD scores, decreased survival, and expanded IFN-γ+, TNF-α+, and IL-17+CD4+ T cells while reducing Foxp3+ Tregs in the recipients of WT but not IL-23Rα-/- T cells. In the xeno-GVHD model, rhIL-39 aggravated GVHD with reduced survival and elevated human T-cell infiltration and inflammatory cytokines. Taken together, IL-39 enhances T-cell pathogenicity in GVHD through IL-23Rα. Conclusion IL-39/IL-39R signaling drives aGVHD pathogenesis and represents a promising therapeutic target for aGVHD while preserving GVL responses. Funding Source NIH, Advancing A Healthier Wisconsin Endowment Topic Categories Transplantation Immunology (TRAN)
2026-07-06 | The application of rituximab during the conditioning regimen prevents Epstein - Barr virus infection following rATG-based haploidentical hematopoietic stem cell transplantation in the era of letermovir for cytomegalovirus prophylaxis.
In the era of letermovir for cytomegalovirus (CMV) prophylaxis, several centers reported that the incidence of Epstein-Barr virus (EBV) infection were significantly increased. To investigate the efficacy and safety of rituximab administration during conditioning regimen following haploidentical hematopoietic stem cell transplantation(haplo-HSCT)in the prevention of post-transplant EBV infection. We conducted a retrospective analysis of 100 patients with acute leukemia or myelodysplastic syndrome who underwent haplo-HSCT. Patients in observation group(R group) received rituximab (375 mg/m²) on day -3 before transplantation due to the presence of donor-specific antibody (MFI ≥ 2000) (n = 25) and patients in control group (C group) did not receive rituximab (n = 75) and donor-specific antibody was low (MFI < 2000). The primary objectives were the incidence of EBV-DNA viremia and PTLD within one-year post-transplantation. Secondary objectives included the incidence of CMV infection, cumulative incidence of acute graft-versus-host disease (aGVHD) and chronic GVHD, 100-day non-relapse mortality (NRM), progression-free survival (PFS), and overall survival (OS). No significant differences were observed in baseline characteristics between the two groups except for primary disease. When compared with the C group, patients in R group exhibited a lower cumulative incidence of EBV viremia within one-year post - transplantation (4.00% vs. 22.67%, P = 0.049) and a lower incidence of aGVHD (28% vs. 50.67%, P = 0.048). There was a trend toward reduction of PTLD in the R group compared with C group (0% vs. 10.67%, P = 0.089).There were no significant differences of the incidence of CMV viremia (24% vs. 13.33%, P = 0.208), cGVHD (16% vs. 12%, P = 0.607), and 100 - day NRM (4.0% vs. 10.67%, P = 0.313) between two groups. The 2-year OS rates in the R group and C group were 83.8% ± 0.086% and 81.9% ± 0.050% respectively (P = 0.360). The 2-year PFS rates in the R group and C group were 83.8% ± 0.086% and 72.6% ± 0.068% respectively (P = 0.360). The combined use of rituximab during the conditioning regimen may be regarded as an effective strategy for preventing EBV reactivation after rATG - based haplo - HSCT in the era of letermovir for CMV prophylaxis.Prospective randomized controlled trials are still required to further validate the reliability of the results.
other
2026-03-04 | IL1B rs1143627 and IL17A rs8193036 in the risk of Acute Graft Versus Host Disease in pediatric HSCT.
Graft-versus-host disease (GVHD) remains a major complication of allogeneic hematopoietic stem cell transplantation (HSCT). While HLA compatibility is a key determinant, increasing evidence suggests that non-HLA immune gene polymorphisms, particularly those in cytokine genes, contribute to GVHD risk. This study seeks to validate in a pediatric population, cytokine-related single nucleotide polymorphisms (SNPs) associated with acute GVHD (aGVHD) and analyze them in combination with the previously identified HLA risk alleles. Pediatric HSCT recipients were recruited from the CHU Sainte-Justine biobank and a prior European Society for Blood and Marrow Transplantation (EBMT) multicenter study. Twenty-five SNPs in 12 cytokine genes were selected based on published associations with aGVHD. Genotypes were obtained for discovery (n = 87) and replication (n = 154) cohorts and association analyses were conducted in each cohort and in the combined dataset. Two SNPs, IL1B rs1143627 and IL17A rs8193036, were significantly associated with increased risk of aGVHD II-IV (p = 0.019 and p < 0.001, respectively). These associations were strongest in HLA-matched unrelated-donor-recipient pairs for IL1B rs1143627 (p = 0.015) and in all HLA-matched pairs for IL17A rs8193036 (p = 0.004). Notably, carriers of one or both risk alleles combined with HLA-B*15:01 had a markedly elevated risk (HR: 2.14 CI:1.41-3.25, p = 6 ×10⁻⁶). These findings highlight the relevance of non-HLA genetic variants in aGVHD pathogenesis. Incorporating cytokine SNP profiles, especially IL1B rs1143627 and IL17A rs8193036, alongside HLA typing may improve donor selection and guide individualized aGVHD prophylaxis.
2026-01-07 | Acute graft-versus-host disease
Despite current advances in graft-versus-host disease (GvHD) prophylaxis, it remains one of the leading causes of morbidity and mortality after hematopoietic cell transplantation (HCT). The first-line therapy for acute GvHD is systemic corticosteroids, but about half of affected patients needs a second-line treatment. Ruxolitinib has been recommended for steroid-refractory GvHD, but treatment costs and adverse events such as cytopenias and infections are limitations. The main second-line alternatives for children are: basilixmab, an anti-interleukin-2-receptor monoclonal antibody, which showed good responses in skin and gut manifestations; extracorporeal photopheresis, treatment that preserves graft-versus-leukemia effect due to its steroid sparing and immunomodulatory actions, and mesenchymal stem cells, another non-pharmacological strategy that can be combined with the options mentioned before in severe acute GvHD. Novel therapeutical agents are emerging, but their efficacy and safety need further investigation in pediatric patients. We reviewed clinical studies and published recommendations on pediatric acute GvHD that were presented in debate rounds with GvHD experts of the Pediatric Group of the Brazilian Society for Cellular Therapy and Bone Marrow Transplantation. The goal of this consensus is to standardize the prophylaxis, diagnosis, grading, and treatment of acute GvHD among Brazilian pediatric HCT centers, to improve post-transplant outcomes.
2025-11-03 | Comparative efficacy and safety of ruxolitinib and remestemcel-l in the treatment of steroid-refractory acute graft-versus-host disease: Systematic review and meta-analysis
Abstract Introduction: Steroid-refractory acute graft-versus-host disease (SR-aGVHD) remains a significant post-transplant challenge, often unresponsive to conventional therapies. Among the new treatment options, Ruxolitinib, an FDA-approved Janus kinase (JAK) inhibitor, and Remestemcel-L, a recently FDA-approved mesenchymal stromal cell therapy, offer distinct mechanisms of action. Ruxolitinib targets the JAK-STAT pathway, while Remestemcel-L seeks to restore immune balance through cellular repair. This systematic review and meta-analysis evaluates the efficacy and safety of both therapies, providing insights into their therapeutic potential and informing clinical decisions for managing this life-threatening condition. Methods: A systematic search of MEDLINE, EMBASE, and CENTRAL was conducted for studies on Ruxolitinib and Remestemcel-L in SR-aGVHD up to August 2025. Meta-analysis was performed using Stata 18.0, with risk of bias assessed using ROBS 2.0. Results: Of 1,247 screened studies, 11 met the inclusion criteria, involving 2,732 patients (1,993 in the treatment group and 523 in the control group). Among treatment groups, 644 patients received Remestemcel-L, and 1,349 received Ruxolitinib. In terms of efficacy, Remestemcel-L had an odds ratio (OR) for complete remission of 0.62 (95% CI: 0.42–0.92), while Ruxolitinib showed an OR of 1.37 (95% CI: 0.94–1.98). For overall remission, Remestemcel-L had an OR of 3.41 (95% CI: 1.88–6.21), compared to 2.13 (95% CI: 1.44–3.15) for Ruxolitinib. Regarding overall survival, Remestemcel-L showed an OR of 3.92 (95% CI: 0.78–19.75), while Ruxolitinib had an OR of 4.46 (95% CI: 1.35–15.52). In terms of safety, Remestemcel-L had an Risk Ratio (RR) for hematologic adverse drug reactions (ADR) of 1.20 (95% CI: 0.42–3.52), compared to 1.46 (95% CI: 0.94–2.26) for Ruxolitinib. For cardiac ADR, Remestemcel-L had an RR of 0.64 (95% CI: 0.33–1.26), while Ruxolitinib showed an RR of 0.99 (95% CI: 0.69–1.43). Hepatic ADR had an RR of 1.17 (95% CI: 0.10–14.11) for Remestemcel-L, and 1.82 (95% CI: 0.42–8.81) for Ruxolitinib. For neurological ADR, the RR for Remestemcel-L was 0.95 (95% CI: 0.51–1.76), and for Ruxolitinib, it was 0.94 (95% CI: 0.65–1.36). Both treatments significantly improved quality of life. Conclusion: Both Ruxolitinib and Remestemcel-L demonstrate significant efficacy in treating steroid-refractory acute graft-versus-host disease, with Remestemcel-L showing superior outcomes in complete and overall remission. Both therapies exhibit favorable safety profiles, though clinical decisions should consider the differences in adverse events. Risk of Bias was moderate in the analyzed studies.
2025-08-01 | NK Alloreactivity Evaluation According to KIR-HLA Interaction Models Influences the Outcome of Haploidentical Haematopoietic Stem-Cell Transplantation Based on Post-Transplant Cyclophosphamide.
Haploidentical haematopoietic stem-cell transplantation (haplo-HSCT) is characterised by a high degree of HLA mismatching. Therefore, NK alloreactivity driven by the interactions between KIR and HLA mismatched molecules could benefit its outcome. However, the influence of NK alloreactivity in haplo-HSCT with post-transplant Cyclophosphamide (PTCy) remains controversial. The aim of this work was to investigate the clinical utility of predicting NK alloreactivity according to previously described models in the context of haplo-HSCT with PTCy. We studied 145 patients who underwent this procedure, evaluating the influence of NK alloreactivity in transplant outcomes. Models that disregard the interactions between KIR and HLA evidenced an unsuccessful prediction of the outcomes. On the contrary, approaches based on KIR-HLA interaction were the most accurate to predict transplant outcomes. The analysis of inhibitory KIRs (iKIRs) based on the missing-ligand model showed that the presence of at least two iKIR mismatches (iKIRmm) among the donor-recipient pair was an independent risk factor for acute graft-versus-host disease (aGvHD) grade III‑IV (HR: 3.21, p = 0.021), relapse rate (HR: 2.46, p = 0.046), relapse-free survival (RFS) (HR: 1.96, p = 0.039) and GvHD/relapse-free survival (GRFS) (HR = 2.16, p = 0.008). The analysis of the missing-licensing model showed that the existence of the mismatch KIR2DL1/C2 associated to relapse rate (HR: 4.34, p = 0.002) and more than one iKIRmm correlated to poorer RFS (HR: 2.31, p = 0.038) and GRFS (HR: 2.26, p = 0.022). These results suggest that NK alloreactivity influences the outcome of haplo-HSCT with PTCy and should be incorporated into the donor selection algorithm for this procedure.
2025-05-28 | [Effects of donor T cell stat3 deficiency on acute intestinal graft-versus-host disease in mice].
Objective: To investigate the effects and underlying mechanisms of Stat3 knockout in donor T cells on acute gastrointestinal graft-versus-host disease (GI-aGVHD) . Methods: BALB/c mice were exposed to lethal irradiation and transplanted with bone marrow and spleen cells from BALB/c mice (syngeneic control group), C57BL/6 mice (wild-type T cell group, WT group), or C57BL/6J-Stat3(em1cyagen) mice (Stat3 gene knockout T cell group, Stat3-KO group) via tail vein injection to establish the aGVHD model. The survival rate, body weight changes, and clinical scores of mice were monitored. Cytometric bead array (CBA) was used to detect the concentrations of serum cytokines. Lymphocytes were isolated from tissues for flow cytometric analysis. H&E staining was performed to observe intestinal pathological changes. FITC-dextran assay was conducted to assess intestinal permeability. Immunohistochemistry was used to evaluate the expression of Ki67 and Muc2. Real-Time Quantitative Reverse Transcription PCR (qRT-PCR) was employed to analyze the gene expression levels of Olfm4, Lysozyme, and Muc2 in the small intestine. Metabolomics was conducted to detect metabolites in serum and intestinal tissues. An in vitro GI-aGVHD organoid model was established by coculturing intestinal organoids with allogeneic T cells, where the number and area of small intestinal organoids were recorded. The GVL effect was assessed using luciferase-transfected ALL cells (ALL/Luc) and bioluminescent imaging. Results: Compared with the WT group, Stat3 knockout T cells alleviated body weight loss, reduced symptoms-such as hunchback and diarrhea-in mice, improved survival rate (P<0.05), and reduced serum interleukin (IL) -2, IL-6, interferon-γ, tumor necrosis factor-α, IL-17A, and IL-10 levels (all P<0.05), intestinal inflammatory cell infiltration (P<0.05), and intestinal mucosal permeability. Further, Muc2 and Ki67 expression levels in the small intestine of the Stat3 knockout group were markedly increased, and Olfm4, Lysozyme, and Muc2 gene expression levels were significantly increased (all P<0.05). In vitro, the Stat3 knockout group demonstrated better organoid development than the WT group. Metabolomic analyses indicated that Stat3 knockout in T cells may affect the pathways associated with bile acid secretion and unsaturated fatty acids. ALL/Luc cells in the GVL mouse model proliferated rapidly in the TCD-BM group; however, 80% of the mice in the Stat3-KO group survived tumor-free for >100 days (P<0.05) . Conclusion: Knocking out Stat3 in graft T cells reduces T cell damage to intestinal stem cells, thereby ultimately alleviating GI-aGVHD while maintaining a stable GVL effect.
small molecules
2026-09-30 | Evaluation and Extrapolation of a Tacrolimus Population Pharmacokinetic Model in Adult Recipients of Allogeneic Hematopoietic Cell Transplantation Receiving Post-Transplant Cyclophosphamide.
Allogeneic hematopoietic cell transplant (allo-HCT) is potentially curative for many hematologic diseases but complicated by acute graft-versus-host disease (aGVHD). While tacrolimus remains the cornerstone of aGVHD prophylaxis, regimens are increasingly including post-transplant cyclophosphamide (PTCy). This single-center study evaluated a previously published tacrolimus population pharmacokinetic (popPK) model developed from allo-HCT recipients administered standard (tacrolimus plus methotrexate) aGVHD prophylaxis for generalizability to PTCy recipients. Adult allo-HCT recipients treated with PTCy for aGVHD prophylaxis were included. Applicability of the established popPK model to the PTCy population was based on an evaluation of simulated to observed concentration ratios, and the distribution was interpreted with respect to a clinical equivalence range (0.8 to 1.25). The model was refit using data from both the standard and PTCy cohorts to describe the PK and support extrapolation to the PTCy population. Individual PK parameters from PTCy recipients were used to simulate steady-state concentrations (Ctrough, ss) using the current institutional weight-based dosing strategy and the proposed model-informed precision dosing (MIPD) algorithm. The proportion of patients predicted to experience a subtherapeutic Ctrough, ss (<5 ng/mL) was compared between dosing strategies. Five hundred and ninety-three tacrolimus Ctrough, ss values from 95 allo-HCT recipients who received PTCy were included. The previous model did not successfully predict tacrolimus Ctrough, ss values among PTCy patients, but highlighted similarities between clearance in PTCy and standard aGVHD prophylaxis patients who received reduced-intensity conditioning. Dosing simulations suggested a decreased proportion of PTCy patients would experience subtherapeutic tacrolimus Ctrough, ss with MIPD (3%) compared to conventional weight-based dosing (23%).
2026-09-27 | Successful Management of Severe Hepatic Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in a Child With β-Thalassemia Major: Clinical Lessons From Early Therapeutic Escalation.
Severe hepatic acute graft-versus-host disease can occur early after allogeneic hematopoietic stem cell transplantation without skin involvement, presenting with rapidly progressive cholestatic liver dysfunction. Early recognition and prompt escalation to multimodal immunosuppressive therapy achieve complete biochemical remission and durable hematopoietic recovery, highlighting the crucial role of early, multidisciplinary pediatric management.
2026-09-15 | Chidamide plus venetoclax as effective and safe maintenance therapy in high-risk acute myeloid leukemia and myelodysplastic syndrome post-transplantation.
Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the leading cause of treatment failure in high-risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), yet effective maintenance strategies are currently lacking. The combination of chidamide (CHI) and venetoclax (VEN) represents a novel approach. However, real-world data on its use are limited. In this study, eighteen high-risk transplant recipients received maintenance therapy with CHI (5 mg/day on days 1-7 or 1-14) plus VEN (100 mg on day 1, then 200 mg on days 2-7 or 2-14) every 2 months. Endpoints included overall survival (OS), disease-free survival (DFS), cumulative incidence of relapse (CIR), non-relapse mortality (NRM), and safety. After a median follow-up of 708 days, the 2-year OS and DFS were 73.9% and 56.6%, respectively. The 2-year CIR was 28.9%, and the 2-year NRM rate was 22.5%. The most common adverse events were hematologic, including neutropenia (13 episodes), thrombocytopenia (7), and anemia (7), all of which were manageable. No treatment-related mortality, tumor lysis syndrome, or severe acute graft-versus-host disease (GVHD) occurred. In conclusion, CHI plus VEN as post-transplant maintenance therapy shows encouraging efficacy and a manageable safety profile in high-risk AML/MDS patients, representing a promising strategy for relapse prevention.
2026-09-15 | Cytokine release syndrome in adults with acute leukemia after allo-HCT with posttransplant cyclophosphamide prophylaxis.
Cytokine release syndrome (CRS) is a common complication following allogeneic hematopoietic cell transplantation (allo-HCT) with posttransplant cyclophosphamide (PTCy). However, its incidence, risk factors, and clinical significance remain incompletely characterized. We retrospectively analyzed 362 adult patients with acute leukemia in complete remission who underwent PTCy-based allo-HCT at a single center between 2020 and 2025. CRS was observed in 69 patients (19.1%); all cases were grade 1-2 by the 2019 ASTCT criteria. Incidence differed significantly by donor type: 39.5% in haploidentical, 15.4% in mismatched unrelated (MMUD), 8.0% in matched unrelated, and 1.4% in matched related donor recipients (p < 0.001). On multivariable analysis, CRS risk increased with HLA disparity versus matched donors (MMUD OR 2.92, p = 0.026; haploidentical OR 12.2, p < 0.001), and was higher with peripheral blood than bone marrow grafts (OR 3.59, p = 0.025). CRS was associated with higher incidence of grade II-IV acute graft-versus-host disease (aGVHD) (35 vs 18%, p = 0.002), while survival, non-relapse mortality, and relapse incidence did not differ significantly. Histological examination of CRS-associated cutaneous lesions demonstrated perivascular lymphocytic dermatitis without features of aGVHD. Ruxolitinib administration for extensive cutaneous involvement was associated with resolution of skin manifestations. HLA mismatch and peripheral blood grafts are associated with CRS, which may precede subsequent aGVHD.
2026-09-09 | Thiolutin alleviates acute graft-versus-host disease (aGVHD) in a mouse model of allogeneic hematopoietic stem cell transplantation.
Acute graft-versus-host disease (aGVHD) is a major, life-threatening complication in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), and the development of novel molecular-targeted therapies for aGVHD is urgently needed. Thiolutin (THL), a disulfide-containing antibiotic, inhibits the activity of the BRCC3-containing isopeptidase complex and thereby suppresses NLR pyrin domain-containing protein 3 (NLRP3) inflammasome activation. Here, we investigated the effect of THL on aGVHD in a mouse model of allo-HSCT. We found that THL significantly improved survival in aGVHD recipients, reduced weight loss and clinical scores, and attenuated pathological changes in aGVHD target organs, including the liver, small intestine, and colon. Furthermore, THL diminished donor T-cell activation and infiltration into target organs and promoted the expansion of regulatory T cells. THL also inhibited NLRP3 inflammasome activation and reduced the production of proinflammatory cytokines, including tumor necrosis factor (TNF), interferon γ (IFN-γ), interleukin (IL)-2, IL-17A, and IL-1β. This study reveals a previously unrecognized role of THL in regulating aGVHD and highlights its potential as an anti-inflammatory therapeutic agent for clinical development in patients undergoing allo-HSCT.
cell therapies
2026-09-04 | Graft CD3+/CD4 - CD8- T-cell ratio: a predictor of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation in pediatric patients.
Acute graft-versus-host disease (aGVHD) remains a major complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study investigated the association between the graft CD3+/CD4 - CD8- T-cell ratio and the incidence of aGVHD in pediatric recipients. A total of 112 pediatric patients with high-risk hematologic malignancies undergoing allo-HSCT were enrolled in this retrospective study. Associations between the graft CD3+/CD4 - CD8- T-cell ratio and aGVHD were evaluated using Fine-Gray regression models. Receiver operating characteristic (ROC) analysis was performed to determine the predictive performance and optimal cutoff value of the graft CD3+/CD4 - CD8- T-cell ratio. Spearman's rank correlation coefficient was used to assess correlations among different cellular subsets. The day-100 cumulative incidence of grade II-IV aGVHD was 41.1%. In multivariable analysis, the graft CD3+/CD4 - CD8- T-cell ratio was independently associated with grade II-IV aGVHD. ROC analysis identified 56 as the optimal cutoff value for the graft CD3+/CD4 - CD8- T-cell ratio. Patients with a high ratio had a significantly higher incidence of grade II-IV aGVHD than those with a low ratio (56.3% vs. 20.8%, P < 0.001), whereas no significant differences were observed in disease relapse or cytomegalovirus (CMV) infection. The graft CD4 - CD8- T-cell dose was positively correlated with early peripheral CD4 - CD8- T-cell recovery after transplantation. A higher graft CD3+/CD4 - CD8- T-cell ratio is independently associated with an increased risk of day-100 grade II-IV aGVHD in pediatric allo-HSCT recipients. Optimizing the graft CD3+/CD4 - CD8- T-cell ratio may help mitigate aGVHD, thereby serving as a practical biomarker for individualized aGVHD risk stratification.
2026-08-27 | Keratin 8 enhances the efficacy of mesenchymal stem cells in preventing acute graft-versus-host disease.
Acute graft-versus-host disease (aGVHD) remains a leading cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The development of methods that preserve graft-versus-leukemia (GVL) activity while preventing aGVHD remains a long-sought goal. Recent studies suggest that mesenchymal stem cells (MSCs), particularly human umbilical cord-derived MSCs (HUC-MSCs), are effective at mitigating aGVHD, yet their varied efficacy remains poorly understood. We performed a comprehensive analysis of MSCs heterogeneity through single-cell transcriptomic mapping across nine human tissue sources and identified the keratin 8 high-expression (KRT8+) subpopulation of HUC-MSCs with enhanced functional properties. We further validated the functional roles of the KRT8+ subpopulation through lentivirus-mediated KRT8 overexpression. Bulk RNA sequencing was used to analyze the genomic impact of KRT8 overexpression. Additionally, we examined the effects of KRT8 overexpression on cellular senescence via Western blotting and β-galactosidase (SA-β-gal) staining. The immunosuppressive function of HUC-MSCs was evaluated by coculturing them with CD3+ T Cells and liver organoids. Cell migration ability was assessed through Transwell assays and PKH26 dye labeling in vivo. An MHC-mismatched GVHD mice model (C57BL/6J to BALB/c) was established to test the therapeutic effect of HUC-MSCs. Clinical signs of aGVHD were monitored, and pathological changes were analyzed using hematoxylin and eosin staining. The GVL effect was evaluated through the inoculation of luciferase-transfected A20 cells and bioluminescence imaging. KRT8 was expressed predominantly in HUC-MSCs. Compared with the KRT8 low-expression (KRT8lo) subpopulation of HUC-MSCs, the KRT8+ subpopulation presented increased stemness and reduced immunogenicity. KRT8 overexpression in HUC-MSCs significantly ameliorated aGVHD in vivo. Importantly, increased KRT8 expression in HUC-MSC did not impaire GVL activity in A20 lymphoma cells. Functional experiments further confirmed that HUC-MSCs with increased KRT8 expression significantly reduced cellular senescence by increasing enhancer of zeste homolog 2 (EZH2)-mediated histone h3 lysine 27 trimethylation (H3K27me3). This upregulation resulted in increased secretion of hepatocyte growth factor (HGF). This, in turn, suppressed T-cell proliferation and activation, significantly reducing liver organoid damage in vitro. Our results suggest that the infusion of KRT8+ HUC-MSCs enhances the efficacy of preventing aGVHD but does not interfere with the GVL effect. This strategy represents a promising therapeutic advancement in the setting of allo-HSCT.
2026-08-19 | Fecal microbiota transplantation in the treatment of acute graft-versus-host disease: A retrospective study performed by the Complications Working Party and Pediatric Diseases Working Party of the EBMT.
Acute graft-versus-host disease (aGvHD) is a major cause of non-relapse mortality following allogeneic hematopoietic stem cell transplantation (alloHSCT). While corticosteroids are the standard first-line therapy, approximately half of the patients become steroid-refractory or -dependent (SR/D). Fecal microbiota transplantation (FMT) has emerged as a therapeutic strategy targeting the underlying gut dysbiosis associated with aGvHD. This study presents retrospective data on FMT for SR/D-aGvHD. This retrospective, multicenter study was conducted by the Complications Working Party of the EBMT. Data were collected from 9 centers on patients who received FMT for the treatment of SR/D-aGvHD between 2014 and 2019. The primary endpoint was the overall response rate (ORR) at day 28 post-FMT. Forty-seven patients were analyzed. The primary indication for FMT was gastrointestinal aGvHD (GI-aGvHD). In this heavily pre-treated, ruxolitinib-naïve population, the ORR at day 28 was 60.5%, increasing to 69.2% by day 56. At last follow-up, 23 patients (64% of survivors) had no symptoms of aGvHD. Adverse events related to FMT were reported in 24 patients (51.1%). A clinically significant secondary benefit was the 54.5% decolonization rate of antibiotic-resistant bacteria. In this cohort FMT demonstrated efficacy for SR/D-aGvHD, with response rates comparable to those of modern targeted agents.
2026-08-18 | Extracorporeal Photopheresis in Tandem With Continuous Renal Replacement Therapy: A Case Report.
The use of therapeutic plasma exchange in tandem with continuous renal replacement therapy (CRRT) and extracorporeal membrane oxygenation (ECMO) has been well described; however, evidence showing the use of extracorporeal photopheresis (ECP) in tandem is lacking. Here we report a consult to perform ECP in tandem with CRRT for a 26-year-old female with a history of severe aplastic anemia who underwent allogeneic hematopoietic stem cell transplant, complicated by steroid-refractory acute graft-versus-host disease, vaso-occlusive disease, thrombotic microangiopathy, adenoviremia, and acute renal and respiratory failure. We performed six tandem ECP procedures (seven total) over 19 days, until the patient's decline resulted in compassionate discontinuation of care. During our procedures, CRRT managed the ionized calcium and adjusted the calcium infusion rate accordingly. We encountered red blood cell and optic bowl sensor alarms during ECP. This case, to our knowledge, is the first to describe the inpatient use of ECP in tandem with CRRT.
2026-07-22 | GZMK-expressing tissue-resident memory CD8+ T cells participate in human intestinal acute graft-versus-host disease.
Intestinal acute graft-versus-host disease (aGVHD) is a common life-threatening complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although tissue-resident memory T (TRM) cells are thought to play a pathophysiological role in animal models of aGVHD, little is known about the role of distinct subsets of TRM cells in human intestinal aGVHD. Herein, we combined multiplex immunohistochemical staining with single-cell RNA sequencing to elucidate the differentiation trajectory, lineage commitment, clonal expansion, and functional properties of distinct CD8+ TRM cell subsets in human intestinal aGVHD. We identified a predominant GZMK+CD8+ TRM subset, characterized by the GZMK and CD49A markers. Intestinal aGVHD was associated with infiltration of GZMK+CD8+ T cells with TRM features, which showed enhanced clonal expansion, IFN signaling pathway-associated proinflammatory pathway expression, and lineage bifurcation differentiation properties. High GZMK+CD8+ TRM subset infiltration was associated with greater human intestinal aGVHD severity and poor prognosis. Together, our studies highlight the importance of the GZMK+CD8+ TRM subset in human intestinal aGVHD, and interest for designing GZMK+CD8+ TRM cell-targeted therapies.
proteins
2026-09-24 | Prognostic factors of acute and chronic graft-versus-host disease in pediatric patients undergoing bone marrow haploidentical transplant with post-transplantation cyclophosphamide.
Haploidentical hematopoietic stem cell transplantation has become an important therapeutic option for pediatric patients lacking an HLA-identical donor. This study aimed to identify clinical and transplant-related predictors of graft-versus-host disease in Tunisian children undergoing haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. A retrospective study, conducted at the National Blood Transfusion Center, in collaboration with the National Bone Marrow Transplantation Center, included 47 pediatric patients transplanted between January 2019 and December 2023. Associations with acute and chronic graft-versus-host disease were assessed using contingency tables with odds ratios and 95% confidence intervals, followed by multivariate logistic regression for relevant variables. Forty-eight transplant procedures were analyzed. In the univariate analysis, most parameters, including graft cellular content, conditioning regimen, donor age, underlying disease, donor-specific antibodies and ABO incompatibility, were not associated with graft-versus-host disease. In contrast, donor-recipient sex mismatch significantly increased the risk of acute graft-versus-host disease (OR = 10.0; 95% CI: 2.26-44.20; p = 0.0024) and was confirmed as an independent predictor on multivariate analysis (OR = 17.7; 95% CI: 0.13-297.9; p = 0.0068). No variable emerged as a significant determinant of chronic graft-versus-host disease. In this cohort, donor-recipient sex mismatch was the main risk factor for acute graft-versus-host disease, while no clear predictor was identified for chronic disease. Larger prospective studies are needed to validate these findings and to refine predictive models, with the ultimate aim of optimizing haploidentical hematopoietic stem cell transplantation protocols and improving outcomes.
2026-09-23 | Paeoniflorin prevents acute graft-versus-host disease while preserving graft-versus-tumor effects.
Acute graft-versus-host disease (aGVHD) remains a major complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study investigated the preventive effects of paeoniflorin (PF), a natural monoterpene glycoside, on aGVHD. Candidate herb-derived compounds against aGVHD were screened using SymMap, HERB, ADMETlab, and InflamNat, followed by molecular docking. The preventive effects of PF were evaluated in major histocompatibility complex (MHC)-mismatched murine aGVHD models. An entire-process paeoniflorin (EP-PF) regimen, involving donor pretreatment before transplantation and recipient treatment after transplantation, was proposed for enhancing the preventive effect. Survival, body weight, clinical score, hematopoietic reconstitution, donor T cell infiltration, cytokine and chemokine levels, gut injury, apoptosis, gut microbiota, transcriptomic changes, and graft-versus-tumor (GVT) activity were assessed. PF was identified as a promising multi-target compound for aGVHD prevention. PF reduced clinical severity, body weight loss, and mortality, while improving hematopoietic recovery and increasing hematopoietic stem/progenitor cell (HSPC) numbers. EP-PF regimen showed stronger protection than recipient-only PF administration. Mechanistically, EP-PF reduced intestinal donor cluster of differentiation 4 (CD4) positive and cluster of differentiation 8 (CD8) positive T cell infiltration, partially restored CD4+/CD8+ T cell balance, and reversed inflammatory transcriptional programs in donor T cells. Moreover, EP-PF balanced serum levels of cytokines and chemokines, preserved gut barrier integrity, reduced intestinal apoptosis, and partially corrected gut microbiota dysbiosis. Importantly, EP-PF preserved donor cell-mediated tumor control in a green fluorescent protein (GFP)-labeled A20 GVT model. PF also directly inhibited the proliferation of hematologic tumor cells and promoted their apoptosis in vitro and in vivo. PF prevents experimental aGVHD through coordinated regulation of donor T cell responses, inflammatory mediators, hematopoietic reconstitution, intestinal barrier injury, apoptosis, and gut microbiota, while preserving GVT activity. These findings support PF as a potential prophylactic candidate for allo-HSCT.
2026-09-08 | Etanercept in Steroid-Refractory Acute Graft Versus Host Disease: Clinical Response, Toxicity, and Long-Term Outcomes.
Steroid refractory acute graft versus host disease (SR-aGVHD) is seen in 30%-40% of patients undergoing allogeneic hematopoietic stem cell transplant (allo HSCT). We report our experience with etanercept (ETA) as a first-line treatment for SR-aGVHD during a period when ruxolitinib was not available in India. We retrospectively analysed 43 allo HSCT patients from 2010 to 2019 who received ETA for SR-aGVHD. The primary objective was to assess the overall response rate with etanercept. Secondary objectives included overall survival (OS), organ specific responses, causes of mortality and identification of factors associated with survival and see its utility in the current ruxolitinib era. The response rates (overall response rate [ORR] - complete response [CR] + very good partial response [VGPR] + partial response [PR]) at Day 28 was 69%. The organ-specific ORR was 70% (lower gut), 67% (skin), and 50% (liver). The median OS of responders at Day 28 from ETA start was 6.8 months versus 2.8 months in non-responders (p=0.0008). Patients in whom a reduction in the systemic steroid dose of ≥ 30% by Day 28 from ETA start was possible had a significantly longer median OS (9.5 months versus 3.5 months; p=0.0001). In multivariate analysis, steroid dose reduction of ≥ 30% by Day 28 of the start of ETA was a significant factor for survival (p=0.015). The cause of death in the majority was infection (90%). ETA, used as a second-line agent, has shown an acceptable ORR for SR-aGVHD in our cohort. Despite the good response rates, the group had a high transplantation-related mortality. Infections were the major cause of mortality, and early tapering of systemic steroids may be the key to improving outcomes. In the current ruxolitinib era, etanercept may hold a place in patients where ruxolitinib has failed or is not feasible.
2026-08-09 | Pegtarazimod limits acute graft-versus-host disease mortality and severity in mice and is tolerated in patients.
The success of allogeneic hematopoietic cell transplantation (allo-HCT) is limited by acute graft-versus-host disease (aGVHD). We have previously reported that neutrophils can exacerbate tissue damage caused by conditioning regimens. Pegtarazimod is a synthetic peptide, derived from the capsid protein of human astrovirus serotype 1, that was shown to reduce neutrophil effector functions. Therefore, we evaluated the therapeutic activity of pegtarazimod against aGVHD. Pegtarazimod significantly reduced aGVHD-related mortality, histological aGVHD severity, and pro-inflammatory cytokines in multiple in vivo mouse models, while maintaining the anti-leukemia effect. Mechanistically, pegtarazimod reduced inflammation by decreasing ROS production as investigated using allo-HCT recipient mice with genetic inactivation of NADPH oxidase (NOX2) in the bone marrow. In addition to the anti-inflammatory effect, pegtarazimod protected intestinal organoids against TNF-induced toxicity and oxidative DNA damage. In the phase-2 clinical trial AURORA, pegtarazimod treatment was well-tolerated in patients with corticosteroid-refractory (SR) aGVHD (NCT06343792) with an overall response rate (ORR) of 4/7 patients at day 28. In summary, pegtarazimod reduced aGVHD in mice by suppressing pro inflammatory neutrophil effector functions and preserving enterocyte integrity. The clinical trial data support tolerability of pegtarazimod in aGVHD patients and further studies are needed to determine efficacy.
2026-07-31 | Gastrointestinal acute graft versus host disease: a translational perspective from pathogenesis to precision prevention and treatment.
Allo-HSCT represents a curative option for various hematological disorders. However, aGVHD remains the leading cause of non-relapse mortality following transplantation. The gastrointestinal tract is the most severely affected and prognostically unfavorable target organ in aGVHD, driven by donor T-cell-mediated epithelial damage, microbiota dysbiosis-driven immune amplification, and a self-perpetuating cycle of barrier disruption. Recent multi-omics studies have identified key pathogenic mechanisms, including microbiota-driven MHC-II expression and immunomodulation by microbial metabolites. Biomarker-driven risk stratification using the MAGIC algorithm has shifted management toward precision medicine, while targeted agents such as ruxolitinib, vedolizumab, and microbiota-directed interventions are reshaping therapeutic strategies. Novel interventional modalities, including FMT, recombinant LCN2, and specific bile acids, have forged innovative avenues that synergize microbiota-directed approaches with immunomodulation for the prevention and treatment of GI-aGVHD. This review systematically delineates the latest advances in the pathogenesis, risk stratification, and therapeutic strategies for GI-aGVHD, and envisions future directions for precision medicine centered on personalized microbiota-immune interventions.
antibodies
2026-09-29 | Graft-Versus-Tumour Effect Following Allogeneic Haematopoietic Stem Cell Transplantation in a Paediatric Patient With Mogamulizumab-Treated Primary Cutaneous Peripheral T-Cell Lymphoma.
Primary cutaneous peripheral T-cell lymphoma, not otherwise specified (pcPTCL-NOS), is exceptionally rare in children, and evidence guiding diagnosis and treatment is limited. A 10-year-old boy with pcPTCL-NOS refractory to chemotherapy received mogamulizumab prior to allogeneic haematopoietic stem cell transplantation (allo-HSCT). Despite a 60-day washout period, he developed prolonged steroid-refractory acute graft-versus-host disease requiring ruxolitinib and extracorporeal photopheresis. Concurrently, transient skin lesions developed at previous lymphoma sites and regressed spontaneously, with biopsy supporting the interpretation of visible graft-versus-lymphoma. This case underscores the need to optimise allo-HSCT timing after mogamulizumab and preserve graft-versus-lymphoma effect while limiting graft-versus-host disease. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
2026-09-01 | Association of Nutrition Intake Adequacy with Clinical Outcomes in Hospitalized Hematopoietic Cell Transplant Patients: A Retrospective Cohort Study.
Patients undergoing hematopoietic cell transplantation (HCT) face nutrition-impacting symptoms that compromise oral intake and increase malnutrition risk. The independent relationship between nutrition intake adequacy and clinical outcomes in this population remains incompletely characterized. To determine whether adequate intake (≥75% of estimated needs) during HCT admission is independently associated with hospital length of stay (LOS), 30-day readmission, and acute graft-versus-host disease (GVHD). Twelve-month retrospective cohort study using electronic medical records between June 15, 2022 - June 15, 2023. Nutrition intake was averaged across admission from registered dietitian assessments and categorized as adequate (≥75%) or inadequate (<75%). /Setting: 283 adults (85 autologous, 198 allogeneic) aged ≥18 years admitted to Stanford Health Care for HCT with a length of stay ≥7 days. Hospital LOS, 30-day readmission, and acute GVHD within 100 days. Multivariable linear regression for LOS and logistic regression for readmission and GVHD, each adjusted for age, gender, race/ethnicity, and BMI. In autologous HCT patients, adequate intake was independently associated with shorter LOS (β = -1.91 days, 95% CI -3.33 to -0.48; P = 0.009), and malnutrition at discharge with longer LOS (β = 1.43 days, 95% CI 0.02 to 2.91; P = 0.04). Sensitivity analyses for autologous HCT patients with adequate intake, excluding patients who received enteral or parenteral nutrition support, did not alter these findings (β = -1.51 days, 95% CI -2.99 to -0.03; P = 0.048). In allogeneic patients, no significant associations were found between intake and LOS after adjustment. Intake was not associated with 30-day readmission or acute GVHD in either group. Among autologous HCT patients, adequate intake was associated with shorter LOS and discharge malnutrition with longer LOS. Optimizing nutritional status may help improve outcomes and reduce hospitalization in this population.
2026-08-21 | Safety and Efficacy of Vedolizumab for the Patients With Gastrointestinal Acute Graft-Versus-Host Disease Refractory to Steroid Treatment After Allogeneic Hematopoietic Stem Cell Transplantation: A Real-World, Retrospective Multicenter Study (VAST Study).
Steroid-refractory (SR) gastrointestinal (GI) acute graft-versus-host disease (aGVHD) is the major cause of early mortality after allogeneic hematopoietic stem cell transplantation. Vedolizumab could be used as the second- or third-line treatment of GI-aGVHD. Our real-world, retrospective multicenter study, in which 100 SR-GI-aGVHD patients who received vedolizumab were enrolled, confirmed its effectiveness. Note that 411 SR-GI-aGVHD patients who received the best available treatments (BATs) during the same period were enrolled as controls. Inverse probability of treatment weighting (IPTW) and propensity score matching (PSM) were conducted as sensitivity analyses. The overall response rates (ORRs) for SR-GI-aGVHD on day 28 and at any time point were 68.0% and 81.0%, respectively, and the 2-year probabilities of overall survival and nonrelapse mortality were 58.3% and 31.9%, respectively, after vedolizumab treatment. Multivariate analysis revealed that initiating vedolizumab treatment within 7 days after SR-aGVHD onset could help improve the ORR. In the sensitivity analysis, compared with the BATs, vedolizumab improved the ORR and complete response rate, particularly in the stage 3-4 SR-GI-aGVHD subgroup, and it reduced the infection rate after IPTW and PSM adjustment. These findings confirmed the efficacy of vedolizumab in a real-world setting, which can help to control SR-GI-aGVHD more effectively and safely.
2026-07-28 | IL-39/IL-39R Signaling Drives Acute Graft-versus-Host Disease by Promoting Pathogenic T-Cell Responses 2259690
Abstract Introduction Acute graft-versus-host disease (aGVHD) remains a life-threatening complication of allogeneic hematopoietic cell transplantation. Among IL-12 family cytokines, the newly identified IL-39, composed of IL-23p19 and EBI3, ligands IL-39 receptor, a complex of IL-23Rα and gp130. IL-39 has been implicated in inflammatory disorders, but its contribution to aGVHD and graft-versus-leukemia (GVL) remains undefined. Methods Murine and human T cells were stimulated with allogeneic APCs in the presence of recombinant human IL-39 (rhIL-39) to test the effect of IL-39 in T-cell response in vitro. Proximity ligation assay (PLA) was used to detect IL-23Rα/GP130 heterodimerization. T-cell pathogenicity in GVHD was measured in murine allogeneic bone marrow transplantion (BMT). The GVL activity was assessed using MLL-AF9 leukemia challenge. A xenogeneic GVHD (xeno-GVHD) model with human PBMCs was used to evaluate IL-39’s effect on human T-celll responses. Results rhIL-39 enhanced proliferation and production of IFN-γ, TNF-α, and GM-CSF, promoted Th1/Th17 polarization, and suppressed Foxp3+Treg differentiation in murine and human T cells. It induced robust STAT1/3 phosphorylation in IL-23Rαhigh Th17 cells and PLA assay confirmed IL-23Rα/gp130 heterodimerization. In murine BMT models, recipients receiving IL-23Rα-/- or DKO donor cells exhibited less GVHD compared to those of WT or IL-12Rβ1-/- cells while preserving GVL activity. rhIL-39 markedly increased GVHD scores, decreased survival, and expanded IFN-γ+, TNF-α+, and IL-17+CD4+ T cells while reducing Foxp3+ Tregs in the recipients of WT but not IL-23Rα-/- T cells. In the xeno-GVHD model, rhIL-39 aggravated GVHD with reduced survival and elevated human T-cell infiltration and inflammatory cytokines. Taken together, IL-39 enhances T-cell pathogenicity in GVHD through IL-23Rα. Conclusion IL-39/IL-39R signaling drives aGVHD pathogenesis and represents a promising therapeutic target for aGVHD while preserving GVL responses. Funding Source NIH, Advancing A Healthier Wisconsin Endowment Topic Categories Transplantation Immunology (TRAN)
2026-07-06 | The application of rituximab during the conditioning regimen prevents Epstein - Barr virus infection following rATG-based haploidentical hematopoietic stem cell transplantation in the era of letermovir for cytomegalovirus prophylaxis.
In the era of letermovir for cytomegalovirus (CMV) prophylaxis, several centers reported that the incidence of Epstein-Barr virus (EBV) infection were significantly increased. To investigate the efficacy and safety of rituximab administration during conditioning regimen following haploidentical hematopoietic stem cell transplantation(haplo-HSCT)in the prevention of post-transplant EBV infection. We conducted a retrospective analysis of 100 patients with acute leukemia or myelodysplastic syndrome who underwent haplo-HSCT. Patients in observation group(R group) received rituximab (375 mg/m²) on day -3 before transplantation due to the presence of donor-specific antibody (MFI ≥ 2000) (n = 25) and patients in control group (C group) did not receive rituximab (n = 75) and donor-specific antibody was low (MFI < 2000). The primary objectives were the incidence of EBV-DNA viremia and PTLD within one-year post-transplantation. Secondary objectives included the incidence of CMV infection, cumulative incidence of acute graft-versus-host disease (aGVHD) and chronic GVHD, 100-day non-relapse mortality (NRM), progression-free survival (PFS), and overall survival (OS). No significant differences were observed in baseline characteristics between the two groups except for primary disease. When compared with the C group, patients in R group exhibited a lower cumulative incidence of EBV viremia within one-year post - transplantation (4.00% vs. 22.67%, P = 0.049) and a lower incidence of aGVHD (28% vs. 50.67%, P = 0.048). There was a trend toward reduction of PTLD in the R group compared with C group (0% vs. 10.67%, P = 0.089).There were no significant differences of the incidence of CMV viremia (24% vs. 13.33%, P = 0.208), cGVHD (16% vs. 12%, P = 0.607), and 100 - day NRM (4.0% vs. 10.67%, P = 0.313) between two groups. The 2-year OS rates in the R group and C group were 83.8% ± 0.086% and 81.9% ± 0.050% respectively (P = 0.360). The 2-year PFS rates in the R group and C group were 83.8% ± 0.086% and 72.6% ± 0.068% respectively (P = 0.360). The combined use of rituximab during the conditioning regimen may be regarded as an effective strategy for preventing EBV reactivation after rATG - based haplo - HSCT in the era of letermovir for CMV prophylaxis.Prospective randomized controlled trials are still required to further validate the reliability of the results.
other
2026-03-04 | IL1B rs1143627 and IL17A rs8193036 in the risk of Acute Graft Versus Host Disease in pediatric HSCT.
Graft-versus-host disease (GVHD) remains a major complication of allogeneic hematopoietic stem cell transplantation (HSCT). While HLA compatibility is a key determinant, increasing evidence suggests that non-HLA immune gene polymorphisms, particularly those in cytokine genes, contribute to GVHD risk. This study seeks to validate in a pediatric population, cytokine-related single nucleotide polymorphisms (SNPs) associated with acute GVHD (aGVHD) and analyze them in combination with the previously identified HLA risk alleles. Pediatric HSCT recipients were recruited from the CHU Sainte-Justine biobank and a prior European Society for Blood and Marrow Transplantation (EBMT) multicenter study. Twenty-five SNPs in 12 cytokine genes were selected based on published associations with aGVHD. Genotypes were obtained for discovery (n = 87) and replication (n = 154) cohorts and association analyses were conducted in each cohort and in the combined dataset. Two SNPs, IL1B rs1143627 and IL17A rs8193036, were significantly associated with increased risk of aGVHD II-IV (p = 0.019 and p < 0.001, respectively). These associations were strongest in HLA-matched unrelated-donor-recipient pairs for IL1B rs1143627 (p = 0.015) and in all HLA-matched pairs for IL17A rs8193036 (p = 0.004). Notably, carriers of one or both risk alleles combined with HLA-B*15:01 had a markedly elevated risk (HR: 2.14 CI:1.41-3.25, p = 6 ×10⁻⁶). These findings highlight the relevance of non-HLA genetic variants in aGVHD pathogenesis. Incorporating cytokine SNP profiles, especially IL1B rs1143627 and IL17A rs8193036, alongside HLA typing may improve donor selection and guide individualized aGVHD prophylaxis.
2026-01-07 | Acute graft-versus-host disease
Despite current advances in graft-versus-host disease (GvHD) prophylaxis, it remains one of the leading causes of morbidity and mortality after hematopoietic cell transplantation (HCT). The first-line therapy for acute GvHD is systemic corticosteroids, but about half of affected patients needs a second-line treatment. Ruxolitinib has been recommended for steroid-refractory GvHD, but treatment costs and adverse events such as cytopenias and infections are limitations. The main second-line alternatives for children are: basilixmab, an anti-interleukin-2-receptor monoclonal antibody, which showed good responses in skin and gut manifestations; extracorporeal photopheresis, treatment that preserves graft-versus-leukemia effect due to its steroid sparing and immunomodulatory actions, and mesenchymal stem cells, another non-pharmacological strategy that can be combined with the options mentioned before in severe acute GvHD. Novel therapeutical agents are emerging, but their efficacy and safety need further investigation in pediatric patients. We reviewed clinical studies and published recommendations on pediatric acute GvHD that were presented in debate rounds with GvHD experts of the Pediatric Group of the Brazilian Society for Cellular Therapy and Bone Marrow Transplantation. The goal of this consensus is to standardize the prophylaxis, diagnosis, grading, and treatment of acute GvHD among Brazilian pediatric HCT centers, to improve post-transplant outcomes.
2025-11-03 | Comparative efficacy and safety of ruxolitinib and remestemcel-l in the treatment of steroid-refractory acute graft-versus-host disease: Systematic review and meta-analysis
Abstract Introduction: Steroid-refractory acute graft-versus-host disease (SR-aGVHD) remains a significant post-transplant challenge, often unresponsive to conventional therapies. Among the new treatment options, Ruxolitinib, an FDA-approved Janus kinase (JAK) inhibitor, and Remestemcel-L, a recently FDA-approved mesenchymal stromal cell therapy, offer distinct mechanisms of action. Ruxolitinib targets the JAK-STAT pathway, while Remestemcel-L seeks to restore immune balance through cellular repair. This systematic review and meta-analysis evaluates the efficacy and safety of both therapies, providing insights into their therapeutic potential and informing clinical decisions for managing this life-threatening condition. Methods: A systematic search of MEDLINE, EMBASE, and CENTRAL was conducted for studies on Ruxolitinib and Remestemcel-L in SR-aGVHD up to August 2025. Meta-analysis was performed using Stata 18.0, with risk of bias assessed using ROBS 2.0. Results: Of 1,247 screened studies, 11 met the inclusion criteria, involving 2,732 patients (1,993 in the treatment group and 523 in the control group). Among treatment groups, 644 patients received Remestemcel-L, and 1,349 received Ruxolitinib. In terms of efficacy, Remestemcel-L had an odds ratio (OR) for complete remission of 0.62 (95% CI: 0.42–0.92), while Ruxolitinib showed an OR of 1.37 (95% CI: 0.94–1.98). For overall remission, Remestemcel-L had an OR of 3.41 (95% CI: 1.88–6.21), compared to 2.13 (95% CI: 1.44–3.15) for Ruxolitinib. Regarding overall survival, Remestemcel-L showed an OR of 3.92 (95% CI: 0.78–19.75), while Ruxolitinib had an OR of 4.46 (95% CI: 1.35–15.52). In terms of safety, Remestemcel-L had an Risk Ratio (RR) for hematologic adverse drug reactions (ADR) of 1.20 (95% CI: 0.42–3.52), compared to 1.46 (95% CI: 0.94–2.26) for Ruxolitinib. For cardiac ADR, Remestemcel-L had an RR of 0.64 (95% CI: 0.33–1.26), while Ruxolitinib showed an RR of 0.99 (95% CI: 0.69–1.43). Hepatic ADR had an RR of 1.17 (95% CI: 0.10–14.11) for Remestemcel-L, and 1.82 (95% CI: 0.42–8.81) for Ruxolitinib. For neurological ADR, the RR for Remestemcel-L was 0.95 (95% CI: 0.51–1.76), and for Ruxolitinib, it was 0.94 (95% CI: 0.65–1.36). Both treatments significantly improved quality of life. Conclusion: Both Ruxolitinib and Remestemcel-L demonstrate significant efficacy in treating steroid-refractory acute graft-versus-host disease, with Remestemcel-L showing superior outcomes in complete and overall remission. Both therapies exhibit favorable safety profiles, though clinical decisions should consider the differences in adverse events. Risk of Bias was moderate in the analyzed studies.
2025-08-01 | NK Alloreactivity Evaluation According to KIR-HLA Interaction Models Influences the Outcome of Haploidentical Haematopoietic Stem-Cell Transplantation Based on Post-Transplant Cyclophosphamide.
Haploidentical haematopoietic stem-cell transplantation (haplo-HSCT) is characterised by a high degree of HLA mismatching. Therefore, NK alloreactivity driven by the interactions between KIR and HLA mismatched molecules could benefit its outcome. However, the influence of NK alloreactivity in haplo-HSCT with post-transplant Cyclophosphamide (PTCy) remains controversial. The aim of this work was to investigate the clinical utility of predicting NK alloreactivity according to previously described models in the context of haplo-HSCT with PTCy. We studied 145 patients who underwent this procedure, evaluating the influence of NK alloreactivity in transplant outcomes. Models that disregard the interactions between KIR and HLA evidenced an unsuccessful prediction of the outcomes. On the contrary, approaches based on KIR-HLA interaction were the most accurate to predict transplant outcomes. The analysis of inhibitory KIRs (iKIRs) based on the missing-ligand model showed that the presence of at least two iKIR mismatches (iKIRmm) among the donor-recipient pair was an independent risk factor for acute graft-versus-host disease (aGvHD) grade III‑IV (HR: 3.21, p = 0.021), relapse rate (HR: 2.46, p = 0.046), relapse-free survival (RFS) (HR: 1.96, p = 0.039) and GvHD/relapse-free survival (GRFS) (HR = 2.16, p = 0.008). The analysis of the missing-licensing model showed that the existence of the mismatch KIR2DL1/C2 associated to relapse rate (HR: 4.34, p = 0.002) and more than one iKIRmm correlated to poorer RFS (HR: 2.31, p = 0.038) and GRFS (HR: 2.26, p = 0.022). These results suggest that NK alloreactivity influences the outcome of haplo-HSCT with PTCy and should be incorporated into the donor selection algorithm for this procedure.
2025-05-28 | [Effects of donor T cell stat3 deficiency on acute intestinal graft-versus-host disease in mice].
Objective: To investigate the effects and underlying mechanisms of Stat3 knockout in donor T cells on acute gastrointestinal graft-versus-host disease (GI-aGVHD) . Methods: BALB/c mice were exposed to lethal irradiation and transplanted with bone marrow and spleen cells from BALB/c mice (syngeneic control group), C57BL/6 mice (wild-type T cell group, WT group), or C57BL/6J-Stat3(em1cyagen) mice (Stat3 gene knockout T cell group, Stat3-KO group) via tail vein injection to establish the aGVHD model. The survival rate, body weight changes, and clinical scores of mice were monitored. Cytometric bead array (CBA) was used to detect the concentrations of serum cytokines. Lymphocytes were isolated from tissues for flow cytometric analysis. H&E staining was performed to observe intestinal pathological changes. FITC-dextran assay was conducted to assess intestinal permeability. Immunohistochemistry was used to evaluate the expression of Ki67 and Muc2. Real-Time Quantitative Reverse Transcription PCR (qRT-PCR) was employed to analyze the gene expression levels of Olfm4, Lysozyme, and Muc2 in the small intestine. Metabolomics was conducted to detect metabolites in serum and intestinal tissues. An in vitro GI-aGVHD organoid model was established by coculturing intestinal organoids with allogeneic T cells, where the number and area of small intestinal organoids were recorded. The GVL effect was assessed using luciferase-transfected ALL cells (ALL/Luc) and bioluminescent imaging. Results: Compared with the WT group, Stat3 knockout T cells alleviated body weight loss, reduced symptoms-such as hunchback and diarrhea-in mice, improved survival rate (P<0.05), and reduced serum interleukin (IL) -2, IL-6, interferon-γ, tumor necrosis factor-α, IL-17A, and IL-10 levels (all P<0.05), intestinal inflammatory cell infiltration (P<0.05), and intestinal mucosal permeability. Further, Muc2 and Ki67 expression levels in the small intestine of the Stat3 knockout group were markedly increased, and Olfm4, Lysozyme, and Muc2 gene expression levels were significantly increased (all P<0.05). In vitro, the Stat3 knockout group demonstrated better organoid development than the WT group. Metabolomic analyses indicated that Stat3 knockout in T cells may affect the pathways associated with bile acid secretion and unsaturated fatty acids. ALL/Luc cells in the GVL mouse model proliferated rapidly in the TCD-BM group; however, 80% of the mice in the Stat3-KO group survived tumor-free for >100 days (P<0.05) . Conclusion: Knocking out Stat3 in graft T cells reduces T cell damage to intestinal stem cells, thereby ultimately alleviating GI-aGVHD while maintaining a stable GVL effect.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
28 orphan drug designations for Acute graft versus host disease, including 2 approved therapies.
28 orphan drug designations for Acute graft versus host disease, including 2 approved therapies.
Drug | Therapy type | Orphan designation | Clinical trial status | Sponsor |
|---|---|---|---|---|
allogeneic-unrelated, CD4+ T cells transduced with lentiviral vector encoding full-length human interleukin-10 gene and a truncated (non-signaling) form of the human nerve growth factor receptor | cell therapies | FDA | Tr1X, Inc. | |
universal CAR-T cell injection targeting NKG2D ligands/OX40/CD70/BCMA | cell therapies | FDA | ST Phi Therapeutics Co.,Ltd. | |
human umbilical cord-derived mesenchymal stem cells | cell therapies | FDA | — | Wuhan Optics Valley Vcanbiopharma Co., Ltd. |
xempritolimod | RNAs | FDA | — | CONNEXT Co., Ltd. |
pegtarazimod | small molecules | FDA | ReAlta Life Sciences, Inc. | |
Tetrahydro-2H-pyran-4-yl 7-(2-(cyclopropanecarboxamido)- imidazo[1,2-a]pyridin-6-yl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate hydrochloride | small molecules | FDA | Accropeutics Inc. | |
tregalizumab | antibodies | FDA | — | T-Balance Therapeutics GmbH |
Mesenchymal stem cells (MSCs) primed with interferon gamma (IFNgamma) | cell therapies | FDA | Ossium Health, Inc. | |
Mesenchymal stem cells | cell therapies | FDA | Ossium Health, Inc. | |
apraglutide | peptides | FDA | Ironwood Pharmaceuticals, Inc. | |
Teduglutide | peptides | FDA | 9 Meters Biopharma Inc. | |
Urinary-derived human chorionic gonadotropin and epidermal growth factor | proteins | FDA | University of Minnesota | |
defibrotide | oligonucleotides | FDA | Jazz Pharmaceuticals Ireland Limited | |
acazicolcept | antibodies | FDA | Alpine Immune Sciences | |
acazicolcept | small molecules | FDA | Alpine Immune Sciences | |
recombinant human interleukin 22-human immunoglobulin Fc fusion protein | proteins | FDA | Evive Biotechnology (Shanghai) Ltd. | |
itolizumab | antibodies | FDA | Biocon Limited | |
itolizumab | antibodies | FDA | Biocon Limited | |
Allogeneic mesenchymoangioblast-derived mesenchymal stem cells | cell therapies | FDA | Cynata Therapeutics Limited | |
neihulizumab | antibodies | FDA | AltruBio Inc. (formerly AbGenomics International, Inc.) | |
Human alpha-1-antitrypsin | proteins | FDA | Paul Maher, MD | |
ruxolitinib [Jakafi XR] | small molecules | FDA | Approved | Incyte Corporation |
Recombinant human monoclonal antibody against human complement component C5a | antibodies | FDA | Alexion Pharmaceuticals, Inc. | |
remestemcel-L-rknd [Ryoncil] | cell therapies | FDA | Approved | Mesoblast, Inc. |
Gavilimomab | small molecules | FDA | Amgen | |
Dimerizing drug that binds to mutated Fas protein/drug-binding domain fusion protein (FKBP) | small molecules | FDA | Bellicum Pharmaceuticals, Inc. | |
Humanized anti-tac | antibodies | FDA | Hoffmann-La Roche, Inc. | |
ST1-RTA immunotoxin (SR 44163) | antibodies | FDA | — | Sanofi Winthrop, Inc. |
“Terminated” – programs with discontinued clinical trials, or with no updates reported for 5 years after completion or 12 years after the last trial started.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.